ImmunoCellular Therapeutics, Ltd. (IMUC)
USD 0.15
(53.85%)
USD 0.15
(53.85%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.81 Million USD | -37.05% |
| 2022 | 2.88 Million USD | 10.4% |
| 2021 | 2.61 Million USD | 79.87% |
| 2020 | 1.45 Million USD | 0.0% |
| 2017 | 21.15 Million USD | -12.27% |
| 2016 | 24.11 Million USD | 55.43% |
| 2015 | 15.51 Million USD | 57.36% |
| 2014 | 9.85 Million USD | 4.21% |
| 2013 | 9.46 Million USD | -20.01% |
| 2012 | 11.82 Million USD | 37.11% |
| 2011 | 8.62 Million USD | 67.94% |
| 2010 | 5.13 Million USD | 74.21% |
| 2009 | 2.94 Million USD | -7.18% |
| 2008 | 3.17 Million USD | 36.87% |
| 2007 | 2.32 Million USD | -56.5% |
| 2006 | 5.33 Million USD | 2478.77% |
| 2005 | 206.88 Thousand USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 FY | 1.81 Million USD | -37.05% |
| 2023 Q2 | - USD | 0.0% |
| 2023 Q1 | - USD | -100.0% |
| 2023 Q3 | - USD | 0.0% |
| 2022 Q4 | 734.5 Thousand USD | 7.72% |
| 2022 Q3 | 681.87 Thousand USD | 1.27% |
| 2022 Q1 | 795.6 Thousand USD | 26913.39% |
| 2022 Q2 | 673.33 Thousand USD | -15.37% |
| 2022 FY | 2.88 Million USD | 10.4% |
| 2021 Q3 | 496.43 USD | 0.0% |
| 2021 Q1 | 1 Million USD | 73963.28% |
| 2021 FY | 2.61 Million USD | 79.87% |
| 2021 Q4 | 2945.21 USD | 493.27% |
| 2020 Q3 | 412.27 USD | 0.0% |
| 2020 Q4 | 1359.55 USD | 229.77% |
| 2020 FY | 1.45 Million USD | 0.0% |
| 2018 Q1 | 1.02 Million USD | 137.48% |
| 2018 Q2 | 307.09 Thousand USD | -70.05% |
| 2017 FY | 21.15 Million USD | -12.27% |
| 2017 Q3 | 3.9 Million USD | -65.61% |
| 2017 Q2 | 11.34 Million USD | 107.01% |
| 2017 Q1 | 5.47 Million USD | -25.15% |
| 2017 Q4 | 431.69 Thousand USD | -88.93% |
| 2016 Q1 | 5.83 Million USD | 10.59% |
| 2016 Q4 | 7.31 Million USD | 33.75% |
| 2016 FY | 24.11 Million USD | 55.43% |
| 2016 Q3 | 5.47 Million USD | -0.2% |
| 2016 Q2 | 5.48 Million USD | -6.07% |
| 2015 FY | 15.51 Million USD | 57.36% |
| 2015 Q1 | 3.1 Million USD | 38.53% |
| 2015 Q3 | 3.74 Million USD | 10.58% |
| 2015 Q4 | 5.27 Million USD | 40.91% |
| 2015 Q2 | 3.38 Million USD | 9.24% |
| 2014 Q1 | 2.74 Million USD | 9.45% |
| 2014 Q3 | 2.44 Million USD | 0.7% |
| 2014 FY | 9.85 Million USD | 4.21% |
| 2014 Q2 | 2.42 Million USD | -11.73% |
| 2014 Q4 | 2.23 Million USD | -8.4% |
| 2013 Q1 | 2.34 Million USD | 5.34% |
| 2013 FY | 9.46 Million USD | -20.01% |
| 2013 Q4 | 2.51 Million USD | 3.89% |
| 2013 Q3 | 2.41 Million USD | 10.81% |
| 2013 Q2 | 2.18 Million USD | -7.1% |
| 2012 Q3 | 3.41 Million USD | 9.15% |
| 2012 Q2 | 3.13 Million USD | 2.66% |
| 2012 FY | 11.82 Million USD | 37.11% |
| 2012 Q1 | 3.04 Million USD | 5.77% |
| 2012 Q4 | 2.22 Million USD | -34.75% |
| 2011 Q4 | 2.88 Million USD | 31.06% |
| 2011 FY | 8.62 Million USD | 67.94% |
| 2011 Q1 | 1.71 Million USD | 43.74% |
| 2011 Q2 | 1.82 Million USD | 6.83% |
| 2011 Q3 | 2.19 Million USD | 20.21% |
| 2010 Q1 | 761.97 Thousand USD | -10.83% |
| 2010 Q4 | 1.19 Million USD | -34.93% |
| 2010 Q3 | 1.83 Million USD | 35.58% |
| 2010 FY | 5.13 Million USD | 74.21% |
| 2010 Q2 | 1.35 Million USD | 77.28% |
| 2009 Q4 | 854.49 Thousand USD | 25.94% |
| 2009 Q1 | 614.95 Thousand USD | -12.19% |
| 2009 Q2 | 800.29 Thousand USD | 30.14% |
| 2009 Q3 | 678.49 Thousand USD | -15.22% |
| 2009 FY | 2.94 Million USD | -7.18% |
| 2008 Q1 | 1.19 Million USD | 233.33% |
| 2008 FY | 3.17 Million USD | 36.87% |
| 2008 Q4 | 700.33 Thousand USD | 18.81% |
| 2008 Q3 | 589.44 Thousand USD | -14.21% |
| 2008 Q2 | 687.05 Thousand USD | -42.72% |
| 2007 FY | 2.32 Million USD | -56.5% |
| 2007 Q4 | 359.83 Thousand USD | 26.81% |
| 2007 Q3 | 283.76 Thousand USD | -21.45% |
| 2007 Q2 | 361.23 Thousand USD | -72.55% |
| 2007 Q1 | 1.31 Million USD | -73.86% |
| 2006 FY | 5.33 Million USD | 2478.77% |
| 2006 Q1 | 140.41 Thousand USD | 0.0% |
| 2006 Q2 | 67.14 Thousand USD | -52.18% |
| 2006 Q3 | 89.91 Thousand USD | 33.91% |
| 2006 Q4 | 5.03 Million USD | 5497.48% |
| 2005 FY | 206.88 Thousand USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -36.01% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 63.977% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 93.854% |
| Nascent Biotech, Inc. | 2.22 Million USD | 18.546% |
| Rebus Holdings, Inc. | 664 Thousand USD | -173.542% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 95.125% |
| Qrons Inc. | 643.67 Thousand USD | -182.179% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -366.242% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 96.838% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -337.163% |
| Skye Bioscience, Inc. | 13.54 Million USD | 86.593% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 97.907% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 63.067% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -593.978% |
| SQZ Biotechnologies Company | 85.61 Million USD | 97.879% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 37.717% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -20.935% |
| Mesoblast Limited | 5.9 Million USD | 69.225% |
| Marizyme, Inc. | 19.23 Million USD | 90.56% |
| Genus plc | 147.7 Million USD | 98.77% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 79.311% |
| Pharming Group N.V. | 225.49 Million USD | 99.195% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | 11.343% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -35.39% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 78.219% |
| ContraFect Corporation | 56.88 Million USD | 96.807% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 58.801% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -22.828% |
| IMV Inc. | 37.7 Million USD | 95.183% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 34.907% |
| MultiCell Technologies, Inc. | 567.42 USD | -320001.512% |
| ONE Bio Corp. | 6.44 Million USD | 71.813% |
| Accustem Sciences Inc. | 3.74 Million USD | 51.519% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 97.887% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -241.438% |
| Q BioMed Inc. | 3.43 Million USD | 47.148% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 92.651% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 30.873% |
| Biomind Labs Inc. | 994.18 Thousand USD | -82.695% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 98.171% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -3.219% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 72.963% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | 2.577% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 7365.28% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 88.655% |
| Curative Biotechnology, Inc. | 1.83 Million USD | 1.023% |
| GB Sciences, Inc. | 1.42 Million USD | -27.864% |
| Alpha Cognition Inc. | 9.7 Million USD | 81.286% |
| HST Global, Inc. | 140.9 Thousand USD | -1189.02% |
| CSL Limited | 3.44 Billion USD | 99.947% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -61.464% |
| Halberd Corporation | 74.84 Thousand USD | -2326.873% |
| Enzolytics Inc. | 2.17 Million USD | 16.664% |
| Agentix Corp. | 1.37 Million USD | -32.408% |
| Resverlogix Corp. | 12.71 Million USD | 85.712% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 50.247% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.882% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -73.977% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 24.475% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -15.004% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 46.657% |
| AVAX Technologies, Inc. | 7.31 Million USD | 75.154% |
| Zenith Capital Corp. | 8.94 Million USD | 79.69% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.78% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -10326.038% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 26.025% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -959.023% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | 5.445% |
| Kadimastem Ltd | 2.41 Million USD | 24.638% |
| Helix BioMedix, Inc. | 1.97 Million USD | 7.896% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 83.286% |
| BioStem Technologies, Inc. | 22.97 Million USD | 92.094% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -900.81% |
| LadRx Corporation | 3.81 Million USD | 52.35% |
| Cell Source, Inc. | 4.32 Million USD | 58.008% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -96.676% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -96.676% |
| NovAccess Global Inc. | 2.46 Million USD | 26.368% |
| Affymax, Inc. | 39.38 Million USD | 95.388% |
| Itoco Inc. | 919.14 Thousand USD | -97.61% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 57.146% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -62.316% |
| Mobile Lads Corp. | 554.54 Thousand USD | -227.533% |
| CytoDyn Inc. | 18.05 Million USD | 89.942% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -7116.496% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -725.307% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -27.929% |
| SYBLEU INC | 160.87 Thousand USD | -1029.019% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| International Stem Cell Corporation | 5.27 Million USD | 65.541% |
| Bioxytran, Inc. | 3.82 Million USD | 52.454% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -3350.325% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -8828.477% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 94.992% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -12.257% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -146.838% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 41.616% |
| Neutra Corp. | 243.82 Thousand USD | -644.94% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 89.595% |
| PureTech Health plc | 144.59 Million USD | 98.744% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 91.136% |
| IXICO plc | 4.7 Million USD | 61.412% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 79.353% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 98.457% |
| CSL Limited | 3.89 Billion USD | 99.953% |
| Cellectis S.A. | 97.32 Million USD | 98.134% |